Patents by Inventor Eugene R. Heyman

Eugene R. Heyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predicting risk of major adverse cardiac events
    Patent number: 11170896
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: November 9, 2021
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS
    Publication number: 20180233229
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Application
    Filed: April 12, 2018
    Publication date: August 16, 2018
    Applicant: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • Predicting risk of major adverse cardiac events
    Patent number: 9965593
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: May 8, 2018
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • Predicting risk of major adverse cardiac events
    Patent number: 9886553
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 6, 2018
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS
    Publication number: 20150081224
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Application
    Filed: April 3, 2014
    Publication date: March 19, 2015
    Applicant: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS
    Publication number: 20130244236
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 19, 2013
    Applicant: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS
    Publication number: 20120065897
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Application
    Filed: November 18, 2011
    Publication date: March 15, 2012
    Inventors: James V. Snider, Eugene R. Heyman
  • Predicting risk of major adverse cardiac events
    Patent number: 8090562
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: January 3, 2012
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman
  • PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS
    Publication number: 20090264779
    Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 22, 2009
    Applicant: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Eugene R. Heyman